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Transplants for Rhabdomyosarcoma
Patrick J. Stiff,1 Manza-A. Agovi,2 Karen H. Antman,3 Didier Blaise,4 Bruce M. Camitta,5
Mitchell S. Cairo,6 Richard W. Childs,7 John R. Edwards,8 Robert Peter Gale,9
Gregory A. Hale,10 Hillard M. Lazarus,11 Mukta Arora12Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, is cured with conventional
therapy in 70%. However, the 5-year survival for those who relapse is about 30%, and drops to about
15% for those with unfavorable histologies (alveolar/undifferentiated subtypes). We describe outcomes of
62 subjects receiving autologous blood/bone marrow (BM) transplants for RMS between 1989 and 2003,
and reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR).
Histologic subtype was confirmed by reviewing pathology reports. Treatment-related mortality (TRM),
progression-free survival (PFS), and overall survival (OS) were evaluated. Overall, 73% of subjects were
\20 years; 39% had cancer bulk .5 cm, 63% had metastasis at diagnosis, 55% had unfavorable histologies,
92% had cancer responsive to chemotherapy pretransplant, and 67% were in first remission. The 1-year
TRM was 5% (95% confidence interval [CI], 1%-12%) and the 5-year PFS and OS were 29% (95% CI, 18%-
41%) and 32% (95% CI, 21%-44%), respectively. There was only a 4% relapse rate after the first year. There
were no differences in 5-year PFS or survival based on histological subtype, transplant in first remission versus
relapse (36% versus 29%; P5.5), or transplantation for poor-risk histologies in first remission versus relapse
(34% versus 33%; P5.9). Our data indicate that autotransplants for RMS disease are typically done in patients
with disease responsive to chemotherapy pretransplant, with approximately one-third long-term survivors.
Despite high-risk factors, we also found a low TRM, perhaps reflecting the migration from marrow to blood
stem cells as the graft source. Even when performed after relapse for alveolar/undifferentiated histologies,
long-term survivals were seen seemingly better than results with conventional therapies.
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In rhabdomyosarcoma (RMS), the cures have
increased from 25% to 70% when combinations of
surgery, intensive combination chemotherapy, and
radiation therapy are used based on well-described
prognostic factors [1]. Adverse prognostic factors,
which correlate with decreased survival include: larger
size (.10 cm), nonbladder, prostate, extremity or
meningeal primary sites, alveolar or undifferentiated
histologies, and residual disease after the initial surgery
[1-4]. These parameters dictate therapy and predict
outcome. Subjects with favorable histologies without
metastases have 90% cures, whereas subjects with
unfavorable histologies and metastases have only
25% cures. In addition, approximately one-third who
initially respond will relapse, and up to 90% of these
ultimately die of disease progression.
Based on the initial sensitivity of RMS to chemo-
therapy and on the fact that some persons are cured
with conventional therapies, several groups have
studied the use of blood and bone marrow (BM)525
526 Biol Blood Marrow Transplant 16:525-532, 2010P. J. Stiff et al.transplants [5-9]. The procedure is safe, but little can
be concluded about its efficacy because of the number
of transplants reported and the lack of appropriate
controls and randomized trials.
The Center for International Blood and Marrow
Transplantation Research (CIBMTR) has data on
a relatively large number of transplants. Centers that
transplanted subjects for this diagnosis were invited
to submit detailed demographic, treatment, and
follow-up data on their subjects. In this descriptive
analysis, we evaluated treatment-related mortality
(TRM) and overall survival (OS) of the various prog-
nostic groups focusing on remission state at transplant
and favorable versus unfavorable histologic cohorts.PATIENTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP), established in 2004, which comprises a vol-
untary working group of more than 450 transplanta-
tion centers worldwide that contribute detailed data
on consecutive allogeneic and autologous hematopoi-
etic stem cell transplants (SCTs) to a Statistical Center
at the Medical College of Wisconsin in Milwaukee and
the NMDP Coordinating Center in Minneapolis. Par-
ticipating centers are required to report all transplants
consecutively; compliance is monitored by on-site au-
dits. Subjects are followed longitudinally, with yearly
follow-up. Computerized checks for discrepancies,
physicians’ review of submitted data, and on-site audits
of participating centers ensure data quality. Observa-
tional studies conducted by the CIBMTR are
performed in compliance with the Privacy Rule
(HIPAA) as a Public Health Authority, and in compli-
ance with all applicable federal regulations pertaining
to the protection of human research participants as
determined by continuous review of the institutional
review boards of the NMDP and the Medical College
of Wisconsin since 1985.
The CIBMTR collects data at 2 levels: transplant
essential data (TED) and comprehensive report form
(CRF) data. TED data include disease type, age, sex,
pretransplant disease stage, and chemotherapy respon-
siveness, date of diagnosis, graft type (BM- and/or
blood-derived stem cells), high-dose conditioning reg-
imen, posttransplant disease progression and OS, de-
velopment of a new malignancy, and cause of death.
All CIBMTR teams contribute TED data. More de-
tailed disease, pre- and posttransplant clinical informa-
tion are collected on a subset of registered subjects
selected for CRF data by a weighted randomization
scheme. TED and CRF level data are collected pre-transplant, 100 days and 6 months posttransplant and
annually thereafter or until death.
Patients
Between 1989 and 2002, 110 subjects with RMS
who received a first autologous BM and/or peripheral
blood stem cell (PBSC) rescue were registered with the
CIBMTR. Comprehensive clinical data about the dis-
ease and transplant sufficient for analysis was available
for 78 of these subjects. The 32 remaining subjects had
only registration level data. Detailed report forms for
the 32 subjects that were missing relevant clinical
data on disease and transplant characteristics as well
as pathology report forms for all the subjects were re-
quested from teams so as to further confirm the disease
diagnosis. We received pathology report forms and
complete clinical data for only 67 subjects. The trans-
plant teams for the remaining 43 subjects indicated
that the pathology reports were unavailable to review
or did not respond to our multiple requests for data.
We carefully reviewed the pathology report for each
of the 67 subjects to confirm their diagnosis and to deter-
mine their histological subgroup. After further review of
the pathology reports, we excluded 5 subjects (histology:
non-RMS) from our patient population. We defined
poor risk histology (n5 34) as an alveolar or undifferen-
tiated subtype, whereas patients with good risk histology
(n5 21) had embryonal or botryoid subtypes. A total of
62 confirmed subjects from 30 transplant centers, were
used in all of our descriptive analyses.
Study Endpoints
The goal of this study was to describe the clinical
outcomes in subjects with RMS after an autologous
BM or PBSC transplant. The primary endpoints in-
cluded: TRM, progression/relapse, progression-free
survival (PFS), OS, and neutrophil and platelet recov-
ery. TRM was defined as death within 28 days post-
transplant or death without disease progression after
28 days posttransplant. Subjects with disease progres-
sion were censored at the time of progression with pro-
gression/relapse as the competing risk.
Progression/relapse was defined as progressive dis-
ease post-transplant ($28 days) or recurrence. It could
follow a period of ‘‘stable’’ disease posttransplant, or
a partial or complete remission (PR, CR). Progres-
sion/relapse represents new or larger areas of disease
($25% increase in largest diameter) compared to the
best posttransplant disease state. Progression/relapse
was summarized by the cumulative incidence function
estimate with TRM as the competing risk. For analysis
of PFS, subjects were considered treatment failures at
the time of disease progression or death from any
cause. Subjects alive without evidence of RMS
progression were censored at last follow-up. For
analysis of OS, failure was defined as death from any
Table 1. Characteristics of Subjects Who Underwent an
Autologous Bone Marrow or Peripheral Blood Transplant for
Rhabdomysarcoma between 1989 and 2003, Reported to the
CIBMTR
Patient characteristics N (%)
Patient-related:
Number of subjects 62
Number of centers 30
Age, median (range), years 14 (3-40)
0-9 28 (45)
10-19 17 (28)
20-29 12 (19)
30-49 5 ( 8)
Male sex 32 (52)
KPS at transplant $90% 48 (77)
Disease-related:
Tumor burden, > 5 cm 24 (69)
Primary site of tumor
Extremity/limb girdle 20 (35)
Head and neck 21 (37)
Truncal 29 (4)
Visceral/retropreritoneal 12 (21)
Other 2 ( 4)
Metastases at diagnosis? 39 (67)
Metastatic sites at diagnosis
BM ± other (no CNS) 15 (38)
Lungs ± other (no CNS) 14 (36)
Liver ± other 1 ( 3)
CNS only 1 ( 3)
Other 8 (21)
No relapse prior to transplant 39 (67)
No
Yes 19 (33)
$ 12 months initial diagnosis to 1st
recurrence/progression, months
12 (67)
Initial response to chemotherapy
Complete response 25 (45)
Partial response 18 (33)
Stable disease/progressive disease 6 (11)
Not evaluable 6 (11)
Lines of chemotherapy
1 32 (52)
2 20 (32)
3+ 9 (15)
Disease status prior to conditioning
Complete response 36 (61)
Partial response 18 (31)
Stable disease/progressive disease 5 ( 8)
Histology
Alveolar 31 (50)
Embryonal 20 (32)
Botryoid 1 (2)
NA-NOS 7 (11)
Undifferentiated 3 (5)
Transplant-related:
Time from initial diagnosis to
transplant median (range), months
10 (3-83)
< 12 months 39 (63)
$ 12 months 23 (37)
Conditioning regimen
Etopside + Cy + LPAM ± other 6 (10)
Etopside + Cy ± other 19 (31)
Etopside + LPAM ± other 15 (24)
Etopside + Carb ± other 1 (2)
Mel ± other 12 (19)
Cy ± other 6 (10)
Other* 3 (5)
Source of stem cells
Bone marrow 13 (21)
Peripheral blood 43 (69)
Both 6 (10)
Growth factor posttransplant† 50 (81)
(Continued )
Table 1. (Continued )
Patient characteristics N (%)
Planned radiation treatment given
post-transplant
15 (25)
Year of transplant
1989-1991 1 (2)
1992-1994 8 (13)
1995-1997 33 (53)
1998-2000 18 (29)
2001-2003 2 (3)
Median follow-up of survivors,
median (range), months
78 (22-172)
Causes of death
Primary cancer 39 (91)
Interstitial pneumonitis 2 (5)
Organ toxicity 1 (2)
Other cancer 1 (2)
PB indicates peripheral blood; CNS, central nervous system; CR, com-
plete remission; TBI, total body irradiation; Cy, cyclophosphamide; Mel,
melphalan; Carb, carboplatin; IPN, interstitial pnuemoniatis; KPS, Kar-
nofsky score at transplant; BM, bone marrow; CIBMTR, Center for In-
ternational Blood and Marrow Transplant Research.
*Other conditioning regimen (n 5 3): Carboplatin only (n 5 2); Mitox-
antrone + Paclitaxel + Thiotepa (n 5 1).
†Growth factor, granulocyte-colony stimulating factor or granulocyte
macrophage colony-forming unit, was delivered to promote engraft-
ment. This was initiated between day 21 and day 7.
Biol Blood Marrow Transplant 16:525-532, 2010 527Autotransplants for Rhabdomyosarcomacause and alive subjects were censored at time of last
follow-up.
Statistical Analysis
Patient-, disease-, and transplant-related variables
are described for all subjects in Table 1. Probabilities
of TRM, relapse/progression, and neutrophil and
platelet engraftment were calculated using cumulative
incidence estimates [10,11]. The cumulative incidence
calculated for neutrophil and platelet engraftment
treated death as a competing risk, whereas in the
cumulative incidence calculated for TRM, relapse/
progression was treated as the competing risk. Univar-
iate probabilities of PFS and OS were calculated using
the Kaplan-Meier estimator [12]. The Log rank test
was used for comparing survival curves. We also
compared outcomes between subjects who were trans-
planted in first remission versus all others; subjects
presenting with metastatic disease versus those
without metastasis at diagnosis and those in the 2 his-
tological groups in first remission versus those who
had relapsed. Comparisons between these groups
used chi-square statistic for categoric variables and
the Kruskal-Wallis test for continuous variables.RESULTS
Patient Demographics
At the time of transplantation, the median age was
13 years, but 17% were older than 19 years. Of the en-
tire cohort, 35% had limb-girdle and 37% head and
528 Biol Blood Marrow Transplant 16:525-532, 2010P. J. Stiff et al.neck primaries. Tumor diameter.5 cm at time of dis-
ease diagnosis was found in 69% and metastatic disease
was seen in 67%. The most common sites of metastasis
were BM (38%) and lung (36%). Pathology subtypes
included: alveolar (50%) and embryonal (32%). One
patient had botryoid histology and 3 had undifferenti-
ated tumors. Although 78% had chemotherapy respon-
sive disease after induction therapy, only 25 (45%) of
evaluable subjects were in CR. All but 1 patient re-
ceived involved field radiotherapy as part of initial ther-
apy. Of the 62 subjects, 61% were either in a first (52%)
or subsequent CR. One-third of subjects were trans-
planted after relapse. Overall 92% were transplanted
for disease responding to chemotherapy with a third
after 2 regimens and 15% after 3 chemotherapy regi-
mens. The median time from diagnosis to transplant
was 10 months. The conditioning regimens were varied
but included melphalan (Mel) in 44% and etoposide in
84%. Consistent with the timing of this analysis, 79%
received PBSC with (10%) or without BM stem cell
(69%) as the transplant source.
Risk Factors at Transplant: Remission Status and
Histology
There were no initial demographic differences for
those transplanted as consolidation of first remissionTable 2. Patient Characteristic Comparison between Those Subjec
Relapsed Prior to Transplant Before Receiving an Autologous Bone
between 1989 and 2003
First Remission (N 5 38)
N Eval N
Number of subjects 38
Age, <20 years 38 24
KPS $90 38 32
Tumor burden, >5 cm 21 15
Primary site of tumor 36
Extremity/limb girdle 12
Head and neck 14
Truncal 2
Visceral/retropreritoneal 7
Other 1
Metastases at diagnosis 37 30
Metastatic sites at diagnosis 38
BM ± other (no CNS) 12
Lungs ± other (no CNS) 12
Liver ± other
CNS only 1
Other 5
Missing 1
Response to first line of therapy 35
Complete response 14
Partial response 16
Stable disease/progressive disease 1
Not evaluable 4
Disease status prior to conditioning 38
Complete response 20
Partial response 16
Stable disease/progressive disease 2
CNS indicates central nervous system; KPS, Karnofsky score at transplant; BM
All transplants were reported to the CIBMTR.
*Chi-square P-value.
†Not enough numbers within group cells to compute a valid chi-square value.(n 5 38) versus those transplanted after relapse
(n 5 21), including age at diagnosis, primary site,
histology, presence of metastatic disease at transplant,
or response to initial therapy (Table 2). However,
a difference was seen in the percent of subjects
transplanted in CR with 53% versus 73% for the first
remission versus relapse groups, respectively
(P 5 .032), perhaps suggesting a selection bias for
transplanting only subjects whose cancer is responsive
to chemotherapy once they had relapsed. For those
with good risk (n 5 21) versus poor risk histology
(n 5 34), there were no differences in their demo-
graphics (Table 3), although trends were seen for
those with poor risk histology who had a higher
frequency of BM involved at diagnosis (44 versus
14%; P 5 .244), a CR to primary therapy (53% ver-
sus 26%; P 5 .115), and being in a CR at transplant
(70% versus 48%; P 5 .247).
Outcome
At a median follow-up of 78 months for survivors,
19 of 62 (31%) subjects are alive. Of those who died,
91% died of their primary malignancy. For the entire
group, the TRM at 1 year was 5% (95% CI, 1-12);
the 5-year PFS and OS were 29% (95% CI, 18-41)
and 32% (95% CI, 21-44), respectively (Table 4).ts in First Remission Prior to Transplant versus Subjects Who
Marrow or Peripheral Blood Transplant for Rhabdomysarcoma
Relapse (N 5 21)
(%) N Eval N (%) P-Value*
21
(63) 21 18 (86) .263
(84) 21 15 (71) .242
(71) 13 8 (62) .735
19 †
(33) 7 (37)
(39) 7 (37)
(6) —
(19) 4 (21)
(3) 1 (5)
(81) 19 7 (37) .002
7 †
(39) 2 (29)
(39) 1 (14)
— 1 (14)
(3) —
(16) 3 (44)
(3) 2 (29)
20
(40) 11 (55)
(46) 2 (10)
(3) 5 (25)
(11) 2 (10)
20 .032
(53) 15 (75)
(42) 2 (10)
(5) 3 (15)
, bone marrow.
Table 3. Demographics Based on Histologic Subtype
Alveolar/Undifferentiated Embryonal/botryoid
N Eval (%) N Eval (%) P-Value*
Number of subjects 34 21
Age, <20 years 29/34 (85) 12/21(58) .056
Males/evaluable (%)† 15/34 (44) 13/21(62)
KPS $90 27/34(79) 14/20 (67) .291
Tumor burden, >5 cm 21/14(66) 12/9(75) .834
Primary site of tumor 31 18 .095
Extremity/limb girdle 15 (48) 3 (16)
Head and neck 8 (26) 8 (42)
Truncal 1 (3) 1 (5)
Visceral/retropreritoneal 7 (23) 5 (26)
Relapse pretransplant (N 5 32) 12 (37) 8 (38) .965
Response to 1st line of therapy 30 19 .115
Complete response 14 (53) 5 (26)
Partial response 10 (33) 6 (32)
Stable/progressive disease 2 (7) 4 (21)
Not evaluable 2 (7) 4 (21)
Disease status prior to conditioning 33 21 .247
Complete response 23 (70) 10 (48)
Partial response 7 (24) 7 (8)
Stable/progressive disease 2 (6) 3 (14)
Time from dx to tx months (range) 10 (3-83) 10 (4-27) .734
CNS indicates central nervous system; KPS, Karnofsky score at transplant; BM, bone marrow; dx, diagnosis; tx, transplant.
†Not enough numbers within group cells to compute a valid chi-square value.
*Chi-square P-value.
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plant (59%) with only 2 subjects relapsing after a year
and none after 3 years (Figure 1). There were no signif-
icant differences in the TRM, relapse rate, or the
5-year PFS and OS when we compared outcomes be-
tween subjects with poor risk versus good risk histol-
ogy: (5-year PFS 31 [95% CI, 15-49] versus 25%
[95% CI, 9-46]; P 5 .658 and OS 29 [95% CI 14-47]
versus 30% [95% CI 12-51]; P 5 .943) (Table 5).
There were also no differences in 5-year PFS (32
[95% CI 18-48] versus 26% [95% CI 10-48]; P 5
.644) or OS (36 [95% CI 22-52] versus 29% [95%
CI 12-49]; P 5 .532) between those transplanted in
first remission versus relapse (Table 6). Twelve sub-
jects with poor-risk histology were transplanted after
relapse. Their 5-year PFS was 36% (95% CI: 12-65)
and their survival was 33% (Figure 2). This was not
different from the 34% survival rate observed for thoseMonths
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Patients at risk for PFS @ 1 year: N=21
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Patients at risk for PFS @ 8 years N=20
Figure 1. Probability of PFS and OS after autologous transplant for
rhabdomyosarcoma patients.with poor-risk histologies transplanted in first remis-
sion (P 5 .955). Likewise, those with good-risk
histology transplanted in first remission had a similar
outcome to those transplanted in relapse (38% versus
25%; P 5 .270).DISCUSSION
Event-free survival (EFS) and OS of subjects with
RMS has improved significantly over the past 20 years.
Supportive care and outcomes of transplants have also
improved. A review by Weigel and colleagues [13]
evaluated reports containing 389 subjects transplanted
before 2000. They concluded that there was no benefit
to transplants in first remission or after relapse. We
sought to determine whether this was still true in
a more recent cohort.
Our study is one of the largest autotransplant anal-
yses for subjects with RMS, and the only one in the
past 10 years. Because of the rarity of RMS advances
in standard therapy [14-18] and the prior negative re-
ports of transplants [5-9,13,19,20], this series is still
small. However, data collected is quite extensive, and
we believe that some conclusions are possible. Most
of the subjects were high risk, having either an unfa-
vorable histology (61%) and/or metastases at diagnosis
(67%) including a substantial proportion with BM in-
volvement). Only 1 subject had botryoid histology, the
most favorable RMS histology. Approximately two-
thirds were transplanted as consolidation of a first re-
mission, but less than one-half of this group was still
in CR, with another one-third typically transplanted
Table 4. Univariate Probabilities of Outcomes of Subjects
Who Underwent Autologous Ttransplantation for Rhabdo-
mysarcoma, between 1989 and 2003, Reported to theCIBMTR
Outcome of Interest N (Eval) Probability (95% CI)
ANC >0.5  109/L* @ 28 days 62 97 (91-100)%
Platelet recovery $20  109/L* @ 28
days
58 50 (37-63)%
Transplant-related mortality* 62
@ 1 year 5 (1-12)%
@ 3 years 8 (3-17)%
@ 5 years 8 (3-17)%
Progression/relapse* 62
@ 1 year 59 (47-71)%
@ 3 years 63 (50-75)%
@ 5 years 63 (50-75)%
Progression-free survival† 62
@ 1 year 36 (24-48)%
@ 3 years 29 (18-41)%
@ 5 years 29 (18-41)%
Overall survival† 62
@ 1 year 56 (43-68)%
@ 3 years 39 (28-52)%
@ 5 years 32 (21-44)%
CI indicates confidence interval; CIBMTR, Center for International
Blood and Marrow Transplant Research.
*Probabilities of relapse, treatment-related mortality, platelet, and
neutrophil engraftment were calculated using the cumulative incidence
function.
†Probabilities of overall survival and progression-free survival were
calculated using the Kaplan-Meier product limit estimate.
530 Biol Blood Marrow Transplant 16:525-532, 2010P. J. Stiff et al.after a second chemotherapy-induced remission.
Overall one-third of the subjects are alive and disease
free at a median of 78 months posttransplant.
Results of transplant for relapsed disease compare
favorably with prior reports, although subject selection
may bias this comparison. The largest transplant series
to date (98 subjects) for relapsed RMS was reported by
the European Blood and Marrow Transplant (EBMT)Table 5. Univariate Probabilities Comparing Subjects with Alve
Botryoid Histology Who Received an Autologous Transplant for R
CIBMTR
Alveolar/Undifferentiated
Outcome of Interest N (Eval) Probability (95% CI
Treatment-related mortality* 34
@ 1 year 6 (1-18)%
@ 3 years 10 (2-24)%
@ 5 years 10 (2-24)%
Progression/relapse* 34
@ 1 year 48 (31-66)%
@ 3 years 59 (41-76)%
@ 5 years 59 (41-76)%
Progression-free survival† 34
@ 1 year 45 (28-63)%
@ 3 years 31 (15-49)%
@ 5 years 31 (15-49)%
Overall survival† 34
@ 1 year 62 (44-79)%
@ 3 years 45 (27-63)%
@ 5 years 29 (14-47)%
CI indicates confidence interval.
*Probabilities of relapse, treatment-related mortality, platelet, and neutrophil
†Probabilities of overall survival and progression-free survival were calculated
‡Pointwise P-value.in 1997 [9]. Median survival was 8 months; and only
20% of subjects survived long term. The German-
Austrian Pediatric BMT group reported 36 cases.
Four of 9 subjects transplanted in relapse survived
long term [19]. Most other series had \10 subjects
[20]. In Weigel et al’s [13] review of 51 patients trans-
planted in second or third CR or with active disease,
3-year survival was 12%. Thus, although numbers of
subjects transplanted after relapse in our series is lim-
ited and selection biases may operate, their 35% long-
term PFS is encouraging. Results of transplants are
also encouraging for the few subjects with alveolar or
undifferentiated histology transplanted after a relapse
who had a 36% (95% CI, 12–65) 5-year PFS. Analyz-
ing conventional therapy after relapse, the Intergroup
Rhabdomyosarcoma Study Group in 1999 determined
the 5-year survival rate after relapse for subjects with
either alveolar and undifferentiated histologies was
only 5% [8]. They also found that the few long-term
survivors in this group were those who relapsed after
having had localized-disease at diagnosis that was
completely excised; all others died. However, the sub-
jects we analyzed in this subgroup were predominately
transplanted in a CR after salvage chemotherapy.
Thus, responsiveness to salvage chemotherapy may
be a requirement for long-term survival.
Most autotransplant studies in RMS have focused
on subjects receiving transplants as consolidation of
high-risk disease (typically defined as metastases at
presentation). This strategy of transplanting subjects
with the poorest prognosis at diagnosis in first remis-
sion is similar to the approach that has been used effec-
tively in treating patients with neuroblastoma and
Ewing sarcoma. Carli et al. [5] evaluatedolar/Undifferentiated Histology to Subjects with Embyronal/
habdomyosarcoma between 1989 and 2003, Reported to the
Embryonal/Botryoid
) N(Eval) Probability (95% CI) P-Value‡
23
— —
— —
— —
23
75 (54-91)% 0.046
75 (54-91)% 0.232
75 (54-91)% 0.232
23
25 (9-46)% 0.136
25 (9-46)% 0.658
25 (9-46%) 0.658
23
55 (33-76)% 0.621
30 (12-51) % 0.282
30 (12-51) % 0.943
engraftment were calculated using the cumulative incidence function.
using the Kaplan-Meier product limit estimate.
Table 6. Univariate Probabilities Comparing Subjects Who Relapsed Prior to Transplant to Subjects Who Never Relapsed
No Relapse Prior to tx Relapsed Prior to tx
Outcome of Interest N (Eval) Probability (95% CI) N (Eval) Probability (95% CI) P-Value‡
Treatment related mortality* 38 21
@ 1 year 5 (1-15)% – N/A
@ 3 years 5 (1-15)% – N/A
@ 5 years 5 (1-15)% – N/A
Progression/relapse* 38 21
@ 1 year 54 (38-70) % 74 (52-90)% .135
@ 3 years 63 (47 -77) % 74 (52-90)% .400
@ 5 years 63 (47-77) % 74 (52-90)% .400
Progression-free survival† 38 21
@ 1 year 41 (26-57) % 26 (10-48) % .275
@ 3 years 32 (18-48) % 26 (10-48) % .664
@ 5 years 32 (18-48) % 26 (10-48) % .664
Overall survival† 38 21
@ 1 year 53 (37-68) % 62 (41-81) % .487
@ 3 years 39 (25-55) % 43 (23-64) % .800
@ 5 years 36 (22-52) % 29 (12-49) % .532
All subjects received an autologous transplant for rhabdomyosarcoma between 1989 and 2003, reported to the CIBMTR.
*Probabilities of relapse, treatment-related mortality, platelet, and neutrophil engraftment were calculated using the cumulative incidence function.
†Probabilities of overall survival and progression-free survival were calculated using the Kaplan-Meier product limit estimate.
‡Pointwise P-value.
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Figure 2. Probability of PFS and OS after autologous transplant for
poor-risk RMS patients who relapsed prior to transplantation.
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sented with metastases (a group in which survival
is approximately 25% with best standard care).
Requirements for entry were a CR after 6 courses of
chemotherapy. Preparative regimens were predomi-
nantly Mel based. They compared transplant out-
comes to outcomes of 44 subjects who received an
additional 6 cycles of chemotherapy, which they
termed ‘‘contemporaneous controls.’’ There was no
significant difference in the 2 groups in prognostic fac-
tors, yet the 3-year EFS was 30% at 3 years for the
transplant group versus 19% for those receiving che-
motherapy. This difference was not significant, but
there was little power in the analysis because of a small
sample size. A statistically significant difference in time
to relapse was seen, however, favoring transplants.
Other studies of transplants for high-risk subjects
in CR1 are less well controlled but showed similar re-
sults. Boulad and coworkers [6] treated 26 newly diag-
nosed patients with RMS (21), extraosseous Ewings
(2), and undifferentiated sarcoma (3) with intensive
chemotherapy followed by split course radiotherapy.
Subjects achieving a CR or PR received high-dose
Mel and etoposide. Their 2-year OS was 56% (95%
CI 36%-76%) and PFS was 53% (95% CI 33%-
76%). Comparing their results to historic controls
not consolidated with transplant, who had a 2-year
PFS of 30%, they felt that the difference was sufficient
to recommend further trials with a more abbreviated
course of conventional therapy. To improve outcome,
intensification of the preparative regimen has also been
tested. Adding doxorubicin and vincristine to total
body radiation (TBI) and high-dose cyclophospha-
mide (Cy), Horowitz and colleagues [7] in transplanted
patients with RMS in CR after induction-therapy for
unresectable alveolar or embryonal trunk and extrem-ity RMS. All 19 subjects not in CR after induction died
of disease progression. Three of 7 subjects in CR who
decided not to receive a transplant were long-term sur-
vivors, whereas 20 of 65 (31%) who received consoli-
dation autotransplants were long-term event-free
survivors. They concluded that TBI plus high-dose
chemotherapy failed to improve outcomes.
Our subjects transplanted in first remission were
typically high risk, and although they had disease re-
sponsive to chemotherapy, only 40% were in CR,
and only 25% had an embryonal histology. Neverthe-
less, these subjects had a similar outcome to the
selected first CR subjects in the aforementioned
studies. This could reflect improvements in induction
chemotherapy over the past 10 years, or better
supportive care in this more recent series, including
a shift from BM to blood cells grafts. Like the older
studies, we believe that the favorable results in this re-
cent series continue to support the development of
randomized trials both in first remission for high-risk
532 Biol Blood Marrow Transplant 16:525-532, 2010P. J. Stiff et al.disease and after relapse for those with disease respon-
sive to chemotherapy.ACKNOWLEDGMENTS
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